Which is the best semaglutide for weight loss in the UK?

You've searched this because someone mentioned Ozempic, but your GP said Wegovy

It's one of the questions our prescribers hear most weeks: "I was told to try semaglutide, is Ozempic the same as Wegovy?" The honest answer is that the active ingredient is identical, but the licensed use, the dose, and the regulatory approval are not interchangeable.

Ozempic is a once-weekly semaglutide injection made by Novo Nordisk, licensed in the UK for type 2 diabetes. Its highest dose is 2mg. Wegovy is also a once-weekly semaglutide injection from the same manufacturer, licensed for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure or high cholesterol. Wegovy reaches a 2.4mg maintenance dose, and now, following MHRA approval in January 2026, a 7.2mg dose is available for eligible adults. Prescribing Ozempic for weight loss is off-label; the medicine weight-loss readers should be asking about is Wegovy. The NHS semaglutide page sets out both products' licensed roles clearly.

This distinction matters practically, not just legally. NICE's clinical review, the supply chain, and any clinical monitoring are built around the licensed product for the condition being treated. Getting the right medicine means getting the right one.

Wegovy injection versus Wegovy tablets, which format suits your life?

If the goal is weight management, the real comparison most people face is between the Wegovy injection pen and the oral Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in Europe.

The injection follows a titration path starting at 0.25mg, stepping up roughly every four weeks toward a 2.4mg maintenance dose or, for eligible patients, up to 7.2mg. You inject once a week into your abdomen, thigh, or upper arm. The pen is refrigerated at home. In the STEP 1 trial, the 2.4mg dose produced around 15% average weight reduction over 68 weeks, a result that sits comfortably above lifestyle intervention alone, as published in the New England Journal of Medicine.

The tablet starts at 1.5mg daily and escalates through 4mg and 9mg to a 25mg maintenance dose. There is a strict morning ritual: the tablet goes down first thing, on an empty stomach, with a small amount of plain water, and you wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. No refrigeration needed, a genuinely practical advantage for people who travel regularly or simply dislike keeping medicine in the fridge. In phase 3 trials, participants who stayed fully on track averaged around 17% weight loss over 64 weeks; the average across all participants, including those who didn't complete the course, was around 13.6%. You can read more about the best way to take semaglutide for both formats.

There is no universal winner between the two. Someone who travels for work and hates injections may find the tablet far easier to sustain. Someone who forgets tablets or can't reliably take them before eating may do better with the once-weekly pen. A prescriber helps you weigh this up against your medical history, other medicines you take, and your habits.

Where Rybelsus fits, and why it's not the same as the Wegovy tablet

Rybelsus is also an oral semaglutide tablet from Novo Nordisk, and it also uses SNAC as an absorption enhancer. The similarity stops there. Rybelsus comes in 3mg, 7mg, and 14mg strengths, none of which are steps in the Wegovy weight-management schedule. Rybelsus is licensed for type 2 diabetes; it has no UK weight-management licence and should not be described as a lower-dose version of the Wegovy tablet. This isn't splitting hairs: the clinical evidence base, the prescribing criteria, and the regulatory approval all differ. If a source describes Rybelsus as a weight-loss option, treat that as a red flag. For a fuller breakdown of which semaglutide product is best for weight loss, that page covers the evidence in more detail.

It is also worth knowing that the company that makes semaglutide (Novo Nordisk) positions each product for a specific licensed indication. The brand name tells you which one you're dealing with.

How the cost picture looks across semaglutide products

Ozempic and Rybelsus are available on NHS prescription for type 2 diabetes, subject to clinical criteria. Wegovy injection is available on the NHS through specialist weight management services under NICE guidance, though waiting lists are commonly long. The oral Wegovy tablet currently has no NICE appraisal, so NHS access is not yet in place; it is available on private prescription only.

Private pricing across semaglutide weight-management products varies by dose and provider. If cost is part of your thinking, how Wegovy private pricing compares across UK providers is worth reading before you make a decision. One thing the price comparison won't settle on its own is which format fits your clinical profile, and if you're also weighing up whether liraglutide might suit you better, our guide to whether liraglutide or semaglutide is the right choice walks through the key differences. That part takes a prescriber.

Some people find the GI side effects of semaglutide (nausea, bloating, changes to digestion) easier to manage at certain times of day or with certain eating patterns; whether Wegovy helps with bloating is a question that comes up often and has a more nuanced answer than you might expect.

If you'd like a prescriber to review which semaglutide format suits your specific situation, speak to our prescribers through a free consultation, every application is read by a GPhC-registered clinician the same day.